You searched for "intraocular"
PREVIEW: UKISCRS Cornea & Cataract Day
Taking place on Monday 19 May at The Hilton Liverpool (L1 8LW), just a stone's throw away from 2025's RCOphth Annual Congress, you will be able to find the wonderful team from UKISCRS hosting their Cornea & Cataract Day. Our...Third nerve palsy following cataract surgery with sub-Tenon’s anaesthesia
Figure 1: Photograph showing partial ptosis of the right eye two months after surgery (photo by R McLeod). An 83-year-old lady had routine right eye cataract surgery under uncomplicated sub-Tenon’s anaesthesia. She presented two weeks later, explaining that following the...Part 3: The Arclight Project: Implementation workshops
In this three-part series (Click here for Part 1 and Part 2) Andrew Blaikie and his team explore the role and application of the Arclight Device in Imaging of the Eye. The Arclight Project aims to support and enhance the...How good does my vision have to be to drive this thing? Visual standards for various occupations
We can all picture that moment in clinic: you are about to tell someone that they’re no longer legally able to drive, ready to deploy our ‘breaking bad news’ techniques. For some patients this may have been expected, or they...What’s next in retinal imaging? Faster, deeper and full-on
Fast-evolving technological leaps are opening the way toward clinically useful ocular coherence angiography, generating 3-dimensional microvasculature maps without intravenous dye injection, as well as whole-eye imaging, handheld patient-operated optical coherence tomography (OCT) devices and, for challenging vitreoretinal procedures, integrated intraoperative...Chronic dacryocystitis?
Lacrimal drainage system tumours are rare and lymphomas account for less than 10% of these tumours [1]. Most patients presenting with lymphoma infiltration of the lacrimal drainage system have a history of previously diagnosed lymphoma elsewhere. We report a case...
Licence to save: a UK survey of anti-VEGF use for the eye
This comment article highlights the controversy that exists in the choice for anti-VEGF drugs used for treatment of macular oedema and wet age-related macular degeneration (AMD). Two existing licensed drugs for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A...
